Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 2/20 | 0.51 |
| ▸ | TTK | P33981 | 15/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979267 | 0.94 | TTK (0.51) | MERTKTTKAXLCSF1R | |
| SCHEMBL4973381 | 0.93 | TTK (0.46) | MERTKTTKCSF1RSYK | |
| SCHEMBL4764945 | 0.92 | TTK (0.48) | MERTKTTKAXL | |
| SCHEMBL4974126 | 0.91 | TTK (0.45) | MERTKTTKCSF1R | |
| SCHEMBL4766540 | 0.89 | TTK (0.57) | TTK | |
| SCHEMBL4979276 | 0.89 | TTK (0.45) | MERTKTTKCSF1R | |
| SCHEMBL4979254 | 0.89 | TTK (0.58) | MERTKTTKAXL | |
| SCHEMBL4766802 | 0.85 | TTK (0.50) | MERTKTTKAXL | |
| SCHEMBL4767125 | 0.85 | TTK (0.44) | MERTKTTKSYK | |
| SCHEMBL4766824 | 0.85 | TTK (0.48) | MERTKTTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | MERTK 1662/4885TTK 4589/4885MET 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.